Inhibitor Therapeutics, Inc. - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - February 17, 2017

Attached files

file filename
EX-32.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - Inhibitor Therapeutics, Inc.d306040dex322.htm
EX-32.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - Inhibitor Therapeutics, Inc.d306040dex321.htm
EX-31.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - Inhibitor Therapeutics, Inc.d306040dex312.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - Inhibitor Therapeutics, Inc.d306040dex311.htm
EX-10.16 - AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED SUPPLY AND LICENSE AGRREMENT - Inhibitor Therapeutics, Inc.d306040dex1016.htm
EX-10.11 - 1ST AMENDMENT TO EMPLOYMENT AGREEMENT BETWEEN THE COMPANY AND GARRISON J. HASARA - Inhibitor Therapeutics, Inc.d306040dex1011.htm
EX-10.6 - 2ND AMENDMENT TO EMPLOYMENT AGREEMENT BETWEEN THE COMPANY AND NICHOLAS J. VIRCA - Inhibitor Therapeutics, Inc.d306040dex106.htm
10-K - FORM 10-K - Inhibitor Therapeutics, Inc.d306040d10k.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-214207) of our report dated February 17, 2017 included in this Annual Report on Form 10-K of HedgePath Pharmaceuticals, Inc. (the “Company”), relating to the balance sheets of the Company as of December 31, 2016 and 2015, and the related statements of operations, stockholders’ equity and cash flows for the years then ended.

/s/ Cherry Bekaert LLP

Tampa, Florida

February 17, 2017

Inhibitor Therapeutics, Inc. Reports